Abstract
Surgeries in obese patients have increased significantly, leading to a rise in perioperative complications such as embolic events. Preventing these complications in obese patients presents pharmacological challenges and involves optimization of guidelines and follow-up considerations, as well as the need for sufficient evidence to ensure safety with minimal risk. In this literature review, we address aspects of dosing with unfractionated and low-molecular-weight heparins, the role of factor Xa inhibitors, and the initiation and duration of thromboprophylaxis in obese patients undergoing surgery. We also review the current role of inferior vena cava filters as a preventive measure.